S'abonner

Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series - 30/07/20

Doi : 10.1016/S1473-3099(20)30314-5 
Merle M Böhmer, PhD a, b, * , Udo Buchholz, MD d, *, Victor M Corman, MD e, *, f, Martin Hoch, MD a, Katharina Katz, PhD a, Durdica V Marosevic, PhD a, Stefanie Böhm, MSc a, c, g, Tom Woudenberg, PhD a, g, Nikolaus Ackermann, MD a, Regina Konrad, PhD a, Ute Eberle, MD a, Bianca Treis, MD a, Alexandra Dangel, PhD a, Katja Bengs, DVM a, Volker Fingerle, MD a, Anja Berger, MD a, Stefan Hörmansdorfer, DVM a, Siegfried Ippisch a, Bernd Wicklein a, Andreas Grahl, MD a, Kirsten Pörtner, MD c, g, Nadine Muller, MD c, g, Nadine Zeitlmann, MSc d, T Sonia Boender, PhD c, g, Wei Cai, MPH d, Andreas Reich, MD d, Maria an der Heiden, MVN d, Ute Rexroth, MD d, Osamah Hamouda, MD d, Julia Schneider, MSc e, Talitha Veith, MPhil e, Barbara Mühlemann, MPhil e, f, Roman Wölfel, MD f, h, Markus Antwerpen, PhD f, h, Mathias Walter, MSc f, h, Ulrike Protzer, ProfMD f, i, Bernhard Liebl, ProfMD a, j, Walter Haas, ProfMD d, , Andreas Sing, ProfMD a, j, , Christian Drosten, ProfMD e, f, , , Andreas Zapf, MD a,
a Bavarian Health and Food Safety Authority, Oberschleissheim, Germany 
b Institute of Social Medicine and Health Systems Research, Otto-von-Guericke-University, Magdeburg, Germany 
c Postgraduate Training for Applied Epidemiology, Berlin, Germany 
d Robert Koch Institute, Berlin, Germany 
e Institute of Virology, Charité University Medicine, Berlin, Germany 
f German Center for Infection Research, Partner Site Munich and Associated Partner Site Charité, Berlin, Germany 
g ECDC Fellowship Programme, Field Epidemiology Path, European Centre for Disease Prevention and Control, Stockholm, Sweden 
h Bundeswehr Institute of Microbiology, Munich, Germany 
i Institute of Virology, Technical University Munich, Munich, Germany 
j Ludwig-Maximilians University, Munich, Germany 

* Correspondence to: Dr Merle Margarete Böhmer, Department of Infectious Disease Epidemiology & Taskforce Infectiology/Airport Bavarian Health and Food Safety Authority, 85764 Oberschleissheim, Germany Department of Infectious Disease Epidemiology & Taskforce Infectiology/Airport Bavarian Health and Food Safety Authority Oberschleissheim 85764 Germany ** Prof Christian Drosten, Institute of Virology, Charité – University Medicine Berlin, 10117 Berlin, Germany Institute of Virology Charité – University Medicine Berlin Berlin 10117 Germany

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Background

In December, 2019, the newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, causing COVID-19, a respiratory disease presenting with fever, cough, and often pneumonia. WHO has set the strategic objective to interrupt spread of SARS-CoV-2 worldwide. An outbreak in Bavaria, Germany, starting at the end of January, 2020, provided the opportunity to study transmission events, incubation period, and secondary attack rates.

Methods

A case was defined as a person with SARS-CoV-2 infection confirmed by RT-PCR. Case interviews were done to describe timing of onset and nature of symptoms and to identify and classify contacts as high risk (had cumulative face-to-face contact with a confirmed case for ≥15 min, direct contact with secretions or body fluids of a patient with confirmed COVID-19, or, in the case of health-care workers, had worked within 2 m of a patient with confirmed COVID-19 without personal protective equipment) or low risk (all other contacts). High-risk contacts were ordered to stay at home in quarantine for 14 days and were actively followed up and monitored for symptoms, and low-risk contacts were tested upon self-reporting of symptoms. We defined fever and cough as specific symptoms, and defined a prodromal phase as the presence of non-specific symptoms for at least 1 day before the onset of specific symptoms. Whole genome sequencing was used to confirm epidemiological links and clarify transmission events where contact histories were ambiguous; integration with epidemiological data enabled precise reconstruction of exposure events and incubation periods. Secondary attack rates were calculated as the number of cases divided by the number of contacts, using Fisher’s exact test for the 95% CIs.

Findings

Patient 0 was a Chinese resident who visited Germany for professional reasons. 16 subsequent cases, often with mild and non-specific symptoms, emerged in four transmission generations. Signature mutations in the viral genome occurred upon foundation of generation 2, as well as in one case pertaining to generation 4. The median incubation period was 4·0 days (IQR 2·3–4·3) and the median serial interval was 4·0 days (3·0–5·0). Transmission events were likely to have occurred presymptomatically for one case (possibly five more), at the day of symptom onset for four cases (possibly five more), and the remainder after the day of symptom onset or unknown. One or two cases resulted from contact with a case during the prodromal phase. Secondary attack rates were 75·0% (95% CI 19·0–99·0; three of four people) among members of a household cluster in common isolation, 10·0% (1·2–32·0; two of 20) among household contacts only together until isolation of the patient, and 5·1% (2·6–8·9; 11 of 217) among non-household, high-risk contacts.

Interpretation

Although patients in our study presented with predominately mild, non-specific symptoms, infectiousness before or on the day of symptom onset was substantial. Additionally, the incubation period was often very short and false-negative tests occurred. These results suggest that although the outbreak was controlled, successful long-term and global containment of COVID-19 could be difficult to achieve.

Funding

All authors are employed and all expenses covered by governmental, federal state, or other publicly funded institutions.

Le texte complet de cet article est disponible en PDF.

Plan


© 2020  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 8

P. 920-928 - août 2020 Retour au numéro
Article précédent Article précédent
  • Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study
  • Qifang Bi, Yongsheng Wu, Shujiang Mei, Chenfei Ye, Xuan Zou, Zhen Zhang, Xiaojian Liu, Lan Wei, Shaun A Truelove, Tong Zhang, Wei Gao, Cong Cheng, Xiujuan Tang, Xiaoliang Wu, Yu Wu, Binbin Sun, Suli Huang, Yu Sun, Juncen Zhang, Ting Ma, Justin Lessler, Tiejian Feng
| Article suivant Article suivant
  • Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000–17: a financial modelling study
  • Yanfang Su, Ines Garcia Baena, Anton C Harle, Sawyer W Crosby, Angela E Micah, Andrew Siroka, Maitreyi Sahu, Golsum Tsakalos, Christopher J L Murray, Katherine Floyd, Joseph L Dieleman

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.